Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Maxim, Kots"'
Autor:
Dave Singh, Johann Christian Virchow, Giorgio Walter Canonica, Andrea Vele, Maxim Kots, George Georges, Alberto Papi
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous
Externí odkaz:
https://doaj.org/article/b2b7509bb6734f4789c8a2f23e298c9a
Autor:
George Georges, A. Vele, Giorgio Walter Canonica, Christian Virchow, Alberto Papi, Maxim Kots, Dave Singh
Publikováno v:
Airway pharmacology and treatment.
Introduction: Asthma exacerbations cluster by seasons with peaks in the autumn, winter and spring. Aims and Objectives: We evaluated the effect of extra-fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) pressuriz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a039a2a1866990086ba3d6e0bc074aa
https://doi.org/10.1183/13993003.congress-2020.2637
https://doi.org/10.1183/13993003.congress-2020.2637
Autor:
A. Papi, Dave Singh, G.W. Cononica, Florence Zuccaro, J.C. Virchow, Maxim Kots, A. Vele, George Georges
Publikováno v:
B31. ASTHMA CLINICAL TRIALS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed264625e4631c11aa5baa176920b995
https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3005
https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3005
Autor:
Giorgio Walter Canonica, Dave Singh, Maxim Kots, Johann Christian Virchow, George Georges, Alberto Papi, A. Vele
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Background A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e9a2b25d54eb6e03b1017acc07b0c74
http://hdl.handle.net/11392/2426227
http://hdl.handle.net/11392/2426227
Autor:
Johann Christian Virchow, A. Vele, George Georges, Maxim Kots, Dave Singh, Giorgio Walter Canonica, Alberto Papi
The addition of a long-acting muscarinic antagonist (LAMA) is a recognised treatment option for patients whose asthma is uncontrolled with an inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) combination [1]. The data supporting this r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0c218bd54800449a3ed1fdf41d6b19
http://hdl.handle.net/11392/2424696
http://hdl.handle.net/11392/2424696
Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses
Autor:
Alberto Papi, A. Vele, Johann Christian Virchow, Dave Singh, Maxim Kots, George Georges, Giorgio Walter Canonica
Publikováno v:
Journal of Allergy and Clinical Immunology. 148:262-265.e2
Background Previous studies have shown seasonal variation in asthma exacerbations, peaking over the winter months. A single-inhaler triple therapy containing extrafine formulations of the inhaled corticosteroid (ICS) beclomethasone dipropionate (BDP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf21e2c5e00b1387a5dd7548abe84df2
https://doi.org/10.1016/j.jaci.2021.01.007
https://doi.org/10.1016/j.jaci.2021.01.007
Autor:
Johann Christian Virchow, Giorgio Walter Canonica, George Georges, A. Bachiri, A. Vele, Florence Zuccaro, E. Carzana, Maxim Kots, Stefano Petruzzelli
Publikováno v:
Revue des Maladies Respiratoires Actualités. 12:180-181
Introduction Une triple association a dose fixe en particules extrafines (DPB/FF/BG dipropionate de beclometasone/fumarate de formoterol/bromure de glycopyrronium) a ete developpee en solution pour inhalation en flacon pressurise (pMDI) dans le trait
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c578419da1116874b2420c741d44efb7
https://doi.org/10.1016/j.rmra.2019.11.404
https://doi.org/10.1016/j.rmra.2019.11.404
Autor:
Job J.M.H. van Bragt, Ian M. Adcock, Gary Anderson, Elisabeth H.D. Bel, Gert-Jan Braunstahl, Anneke Ten Brinke, John Busby, Giorgio W. Canonica, Hui Cao, Kian Fan Chung, Zsuzsanna Csoma, Donna E. Davies, Barbro Dahlen, Ratko Djukanovic, Céline Genton, Toni Gibson-Latimer, Dominique Hamerlijnck, Liam Heaney, Elise Heuvelin, Ildiko Horvath, Stephanie Korn, Maxim Kots, Piotr Kuna, Namhee Kwon, Renaud Louis, Riad Naddaf, Vicente Plaza, David Ramos Barbon, Levi B. Richards, Sabina Skrgat, Els J.M. Weersink, Valentyna Yasinska, Scott S. Wagers, Anke H. Maitland-Van Der Zee
Publikováno v:
Monitoring airway disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6637a3d4848b1ce29f2eb63d4623d4b9
https://doi.org/10.1183/13993003.congress-2019.oa5354
https://doi.org/10.1183/13993003.congress-2019.oa5354
Autor:
Walter Canonica, A. Vele, George Georges, Maxim Kots, Stefano Petruzzelli, David Singh, Florence Zuccaro, J. Christian Virchow
Publikováno v:
Airway pharmacology and treatment.
Introduction: Persistent airflow limitation (PAL) may predict a positive clinical response to add-on long-acting muscarinic antagonist (LAMA) in asthmatics on inhaled corticosteroids and long-acting β2-receptor agonists (ICS/LABA) Objectives: We eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::749e83b2373d16f2d26145c3212e17ca
https://doi.org/10.1183/13993003.congress-2019.oa5339
https://doi.org/10.1183/13993003.congress-2019.oa5339
Autor:
Piotr Kuna, Walter Canonica, Sandrine Corre, Pierluigi Paggiaro, Stefano Petruzzelli, J. Christian Virchow, A. Vele, George Georges, Maxim Kots
Publikováno v:
Airway pharmacology and treatment.
Introduction: Persistent airflow limitation (PAL) may predict a positive clinical response to add-on long-acting muscarinic antagonist (LAMA) in patients with asthma taking inhaled corticosteroids and long-acting β2-receptor agonists (ICS/LABA). Aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46e36d086a22393d8fd4a151207aee0f
https://doi.org/10.1183/13993003.congress-2019.pa3719
https://doi.org/10.1183/13993003.congress-2019.pa3719